Table 1.

Demographic and Clinical Characteristics of the Patients and Controls.^*

Characteristic	Patients		Controls
	Haploidentical Mesenchymal Stromal Cells (N = 7)	STRO-3+ Mesenchymal Progenitor Cells (N = 24)	MDACC (N = 60)†	CIBMTR (N = 80)
Weight — kg
Median	79	75	75	82
Range	53–95	51–118	48–122	40–170
Age — yr
Median	31	39	32	36
Range	26–55	18–61	18–64	18–61
Diagnosis — no. (%)
AML or MDS	5 (71)	16 (67)	31 (52)	52 (65)
ALL	1 (14)	4 (17)	15 (25)	20 (25)
Non-Hodgkin’s or Hodgkin’s lymphoma	0	3 (12)	5 (8)	7 (9)
CLL	1 (14)	1 (4)	2 (3)	1 (1)
CML or other MPD	0	0	6 (10)	0
Myeloma	0	0	1 (2)	0
Disease status at time of transplantation — no. (%)
Complete remission	1 (14)	12 (50)	26 (43)	49 (61)
First remission	1 (14)	2 (8)	8 (13)	17 (21)
Second or subsequent remission	0	10 (42)	18 (30)	32 (40)
Active disease	6 (86)	12 (50)	34 (57)	31 (39)
Donor–recipient HLA compatibility — no. (%)
6/6	0	1 (4)	4 (7)	4 (5)
5/6	3 (43)	3 (12)	13 (22)	14 (18)
4/6	4 (57)	20 (83)	43 (72)	58 (72)
3/6	0	0	0	2 (2)
Not reported	0	0	0	2 (2)

^*ALL denotes acute lymphocytic leukemia, AML acute myeloid leukemia, CIBMTR Center for International Blood and Marrow Transplant Research, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, and MPD myeloproliferative disorder.

^†Two controls from the M.D. Anderson Cancer Center (MDACC) were excluded owing to lack of engraftment and chimerism documentation.